Most recent studies confirmed the increase in chemotherapy activity within the synergy of CD200 (or CD200R) blockade to cure and to produce immune resistance to metastasis of metastatic breast cancer in mice models [11]. This evidence concerns the gene CD200R1 and breast carcinoma.